Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guangwei Yuan

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Applied Physics Letters|June 17, 2009
Evanescent field response to immunoassay layer thickness on planar waveguidesRongjin Yan, Guangwei Yuan, Matthew D Stephens, et al.
International Journal of Women'S Health|October 3, 2024
Prediction of Unexplained Recurrent Miscarriages Using ThromboelastographyJinjin Xu, Yan Yang, Guixue Guan, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 3, 2025
Predicting the Probability of Residual Axillary Nodal Metastases in Patients With Breast Cancer Treated With Neoadjuvant ChemotherapyThaer Khoury, Haiying Zhan, Xiao Huang, et al.
Human Reproduction (Oxford, England)|October 6, 2023
Predicting risk of blastocyst aneuploidy among women with previous aneuploid pregnancy loss: a multicenter-data-based multivariable modelLimei Zhang, Yuanyuan Yang, Wenjun Wang, et al.
Research Square|May 19, 2025
An integrated machine learning-based prognostic model in head and neck cancer using the systemic inflammatory response index and correlations with patient reported financial toxicityAnurag Singh, Sung Jun Ma, Dukagjin Blakaj, et al.
Cancers|December 11, 2025
Development and External Validation of Integrated Machine Learning-Based Prognostic Model in Oropharyngeal Head and Neck Cancer Using the Systemic Inflammatory Response IndexAnurag K Singh, Sung Jun Ma, Dukagjin Blakaj, et al.
International Journal of Cancer|March 7, 2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumabChristos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Applied Physics Letters|June 17, 2009
Evanescent field response to immunoassay layer thickness on planar waveguidesRongjin Yan, Guangwei Yuan, Matthew D Stephens, et al.
International Journal of Women'S Health|October 3, 2024
Prediction of Unexplained Recurrent Miscarriages Using ThromboelastographyJinjin Xu, Yan Yang, Guixue Guan, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 3, 2025
Predicting the Probability of Residual Axillary Nodal Metastases in Patients With Breast Cancer Treated With Neoadjuvant ChemotherapyThaer Khoury, Haiying Zhan, Xiao Huang, et al.
Human Reproduction (Oxford, England)|October 6, 2023
Predicting risk of blastocyst aneuploidy among women with previous aneuploid pregnancy loss: a multicenter-data-based multivariable modelLimei Zhang, Yuanyuan Yang, Wenjun Wang, et al.
Research Square|May 19, 2025
An integrated machine learning-based prognostic model in head and neck cancer using the systemic inflammatory response index and correlations with patient reported financial toxicityAnurag Singh, Sung Jun Ma, Dukagjin Blakaj, et al.
Cancers|December 11, 2025
Development and External Validation of Integrated Machine Learning-Based Prognostic Model in Oropharyngeal Head and Neck Cancer Using the Systemic Inflammatory Response IndexAnurag K Singh, Sung Jun Ma, Dukagjin Blakaj, et al.
International Journal of Cancer|March 7, 2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumabChristos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, et al.
Pageof 2